Chembio Diagnostics, Inc. Gains 39.84%
Wed, Apr 01, 2020 at 05:30 PM
Chembio Diagnostics, Inc. (CEMI:NASDAQ) jumped higher at $7.16, representing a gain of 39.8%. On Tue 31 Mar 20, CEMI:NASDAQ touched a New 2-Week Intraday High of $5.69. The stock appeared on our News Catalysts scanner on Wed 01 Apr 20 at 04:00 AM in the 'MISCELLANEOUS' category. From Tue 17 Mar 20, the stock recorded 60.00% Up Days and 45.45% Green Days
About Chembio Diagnostics, Inc. (CEMI:NASDAQ)
Chembio Diagnostics Inc develops, manufacture markets & licenses rapid point of care diagnostic tests that detect infectious diseases. Its products are rapid tests for the detection of HIV 1/2 antibodies, & for the detection of HIV & Syphilis antibodies.
Top 10 Gainers:
- Diffusion Pharmaceuticals Inc. (DFFN:NASDAQ), 61.09%
- InflaRx N.V. (IFRX:NASDAQ), 50%
- Dynatronics Corporation (DYNT:NASDAQ), 48.2%
- NovaBay Pharmaceuticals, Inc. (NBY:NYSEMKT), 43.41%
- Alpha Pro Tech, Ltd. (APT:NYSEMKT), 42.38%
- Chembio Diagnostics, Inc. (CEMI:NASDAQ), 39.84%
- Citius Pharmaceuticals, Inc. (CTXR:NASDAQ), 36.64%
- Boxlight Corporation (BOXL:NASDAQ), 35.46%
- Safe-T Group Ltd (SFET:NASDAQ), 32.93%
- Athersys, Inc. (ATHX:NASDAQ), 32.67%